Table of Contents
MAPLE GROVE, Minn. — Upsher-Smith Laboratories Inc. has launched a new savings and support program for Qudexy XR extended-release capsules, a once-daily, broad-spectrum anti-epileptic medication.
Dubbed the “It’s That Simple” program, the initiative is designed to make it easier for doctors to prescribe Qudexy XR (topiramate) and includes a $0 co-payment for eligible patients. Qudexy XR is a once-daily, broad-spectrum antiepileptic drug.
For commercially insured and cash-paying patients, the $0 co-pay offer covers $200 per prescription for a maximum annual savings of $2,400 and is available at pharmacies nationwide via an e-voucher or for download at QudexyXR.com.
Also with the program, patients prescribed Qudexy XR can get started immediately with a free 30-day sample, even when a prior authorization is required, Upsher-Smith said. There’s also a dedicated Qudexy XR support line for patient questions as well as personal assistance with benefit verification and prior authorizations. Requests for prior authorizations can be completed electronically for nearly all health plans.
“Having simplified access to quality, affordable medications is critical to all patients, including those with epilepsy,” stated Rusty Field, president of Upsher-Smith. “The It’s That Simple program for Qudexy XR offers patients affordable access and enhanced support while enabling health care professionals to prescribe the product with greater ease and efficiency.”
Upsher-Smith added taht patients and physicians have more options with Qudexy XR, the only 100% extended-release bead formulation of topiramate, which provides smooth topiramate levels over a 24-hour period with once-daily dosing. All strengths of Qudexy XR capsules — 25 mg, 50 mg, 100 mg, 150 mg and 200 mg — are Food and Drug Administration-approved for use as an intact capsule or via the sprinkle method (opening the capsule and sprinkling its contents onto a small amount of soft food).
Qudexy XR is indicated for the treatment of certain types of seizures, including partial-onset seizures and primary generalized tonic-clonic seizures, in adults and children ages 2 years and older.
